Overall, these findings suggest that although PDE4 inhibitors can be considered as multicytokine blockers with potential therapeutic effects in IBD, further studies are required to improve this type of approach to medical treatment in IBD patients. Here, PDE4A is linked to inflammatory bowel disease.